|
Meca-Lallana JE, Alvarez-Cermeno JC, Casanova Estruch B, Izquierdo Ayuso G, Ortiz Castillo R, Rodriguez-Antiguedad A, Calles Hernandez C; en nombre del Grupo de Estudio LEMVIDA. Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study. Neurologia (Engl Ed). 2024 Jun;39(5):383-391. doi: 10.1016/j.nrleng.2021.06.006. Epub 2023 Apr 26. PubMed PMID: 37116693.
AÑO: 2024; IF: 2.9
|
37116693
|
Meca-Lallana JE, Prieto Gonzalez JM, Caminero Rodriguez AB, Olascoaga Urtaza J, Alonso AM, Duran Ferreras E, Espinosa R, Dotor J, Romera M, Ares Luque A, Perez Ruiz D, Calles C, Hernandez MA, Hervas Garcia M, Mendoza Rodriguez A, Berdei Montero Y, Tellez N, Herrera Varo N, Sotoca J, Presas-Rodriguez S, Querol Gutierrez LA, Hervas Pujol M, Batlle Nadal J, Martin Ozaeta G, Gubieras Lillo L, Martinez Yelamos S, Ramio-Torrenta L, Mallada Frechin J, Belenguer Benavides A, Gascon-Gimenez F, Casanova B, Landete Pascual L, Berenguer L, Navarro L, Gomez Gutierrez M, Duran C, Rodriguez Regal A, Alvarez E, Garcia-Estevez DA, Lopez Real AM, Llaneza Gonzalez MA, Marzo Sola ME, Sanchez-Menoyo JL, Oterino A, Villaverde Gonzalez R, Castillo-Trivino T, Alvarez de Arcaya A, Llarena C. Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study. Neurol Ther. 2023 Dec;12(6):2177-2193. doi: 10.1007/s40120-023-00557-7. Epub 2023 Oct 20. PubMed PMID: 37861931; PubMed Central PMCID: PMC10630277.
AÑO: 2023; IF: 3.9
|
|
Oreja-Guevara C, Tintore M, Meca V, Prieto JM, Meca J, Mendibe M, Rodriguez-Antiguedad A. Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements. Cureus. 2023 Aug 24;15(8):e44056. doi: 10.7759/cureus.44056. eCollection 2023 Aug. PubMed PMID: 37746391; PubMed Central PMCID: PMC10517726.
AÑO: 2023
|
|
Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Erratum In: Lancet Neurol. 2023 Oct;22(10):e11. doi: 10.1016/S1474-4422(23)00336-8. PubMed PMID: 37059507.
AÑO: 2023; IF: 46.5
|
|
Fernandez O, Montalban X, Aguera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, Garcia-Dominguez JM, Hernandez MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Mongay-Ochoa N, Moral E, Oreja-Guevara C, Ramio-Torrenta L, Tellez N, Romero-Pinel L, Rodriguez-Antiguedad A. [15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part I)]. Rev Neurol. 2023 Jul 1;77(1):19-30. doi: 10.33588/rn.7701.2023167. Spanish. PubMed PMID: 37365721; PubMed Central PMCID: PMC10663806.
AÑO: 2023; IF: 0.8
|